13
Participants
Start Date
January 14, 2019
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Dinutuximab
17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
NK Cells
The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
Lenalidomide
25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta
Nationwide Children's Hospital, Columbus
C.S Mott Children's Hospital, Ann Arbor
University of Chicago Comer Children's Hospital, Chicago
Cook Children's Healthcare System, Fort Worth
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Seattle Children's Hospital, Seattle
Children's Hospital Los Angeles, Los Angeles
Childrens Hospital Boston, Dana-Farber Cancer Institute., Boston
Cincinnati Children's Hospital Medical Center, Cincinnati
Children's Hospital of Philadelphia, Philadelphia
Collaborators (1)
Nationwide Children's Hospital
OTHER
United Therapeutics
INDUSTRY
New Approaches to Neuroblastoma Therapy Consortium
OTHER